What question did this study set out to answer?

This analysis aims to compare the prognostic value of IPSS, IPSS-R, and IPSS-M in predicting outcomes for patients with myelodysplastic syndromes based on treatment.

January 25, 2026Acta Haematologica

IPSS, IPSS-R and IPSS-M had no identical prognostic power depending on treatment in myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

GAGhada AbichouUniversité Côte d'Azur MLMichael LoschiInserm RSRinzine SammutCentre Hospitalier Universitaire de Nice

Discussion

Member takes

Implication

Retrospective analysis compares prognostic scores in myelodysplastic syndromes, indicating limitations in treatment predictions.

Key Points

This analysis aims to compare the prognostic value of IPSS, IPSS-R, and IPSS-M in predicting outcomes for patients with myelodysplastic syndromes based on treatment.
Conducted a retrospective analysis of 394 MDS patients.
Calculated IPSS, IPSS-R, and IPSS-M scores at diagnosis.
Used Sankey diagrams for visual comparison of risk stratification across scoring systems.
IPSS-M reclassified 41.9% of patients, with 20.2% upstaged and 21.7% downstaged.
All scoring systems showed significant overall survival stratification (p<0.001).
IPSS failed to predict overall survival in azacitidine-treated patients, and none predicted for ESA-treated patients.

Cite This Study

Abichou et al. (2026) studied this question.

synapsesocial.com/papers/6975b1eafeba4585c2d6d67a https://doi.org/10.1159/000549858

View Full Paper

Ask AI

Bookmark

January 25, 2026Acta Haematologica

IPSS, IPSS-R and IPSS-M had no identical prognostic power depending on treatment in myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

GAGhada AbichouUniversité Côte d'Azur MLMichael LoschiInserm RSRinzine SammutCentre Hospitalier Universitaire de Nice

Discussion

Member takes

Implication

Retrospective analysis compares prognostic scores in myelodysplastic syndromes, indicating limitations in treatment predictions.

Key Points

This analysis aims to compare the prognostic value of IPSS, IPSS-R, and IPSS-M in predicting outcomes for patients with myelodysplastic syndromes based on treatment.
Conducted a retrospective analysis of 394 MDS patients.
Calculated IPSS, IPSS-R, and IPSS-M scores at diagnosis.
Used Sankey diagrams for visual comparison of risk stratification across scoring systems.
IPSS-M reclassified 41.9% of patients, with 20.2% upstaged and 21.7% downstaged.
All scoring systems showed significant overall survival stratification (p<0.001).
IPSS failed to predict overall survival in azacitidine-treated patients, and none predicted for ESA-treated patients.

Cite This Study

Abichou et al. (2026) studied this question.

synapsesocial.com/papers/6975b1eafeba4585c2d6d67a https://doi.org/10.1159/000549858

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark